Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
Open Access
- 30 June 2024
- journal article
- research article
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (3) , 161-166
Abstract
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.Keywords
This publication has 31 references indexed in Scilit:
- Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious pubertyEuropean Journal of Endocrinology, 2006
- Serum Luteinizing Hormone Rises Within Minutes After Depot Leuprolide Injection: Implications for Monitoring TherapyPediatrics, 2002
- Increased Final Height in Precocious Puberty after Long-Term Treatment with LHRH Agonists: The National Institutes of Health ExperienceThe Journal of Clinical Endocrinology & Metabolism, 2001
- Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious pubertyEuropean Journal of Endocrinology, 1999
- Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.Archives of Disease in Childhood, 1996
- Spontaneous serum gonadotropin concentrations in the evaluation of precocious pubertyThe Journal of Pediatrics, 1995
- Adult height in girls with idiopathic true precocious puberty.The Journal of Clinical Endocrinology & Metabolism, 1994
- Superactive Gonadotropin-Releasing Hormone AgonistsAnnual Review of Medicine, 1983
- Short-Term Treatment of Idiopathic Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing HormoneNew England Journal of Medicine, 1981
- Tables for predicting adult height from skeletal age: Revised for use with the greulich-pyle hand standardsThe Journal of Pediatrics, 1952